<DOC>
	<DOCNO>NCT01692483</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy abiraterone acetate male Filipino patient advance metastatic castration resistant prostate cancer ( CRPC ) receive prior chemotherapy contain taxane .</brief_summary>
	<brief_title>Post-marketing Surveillance Study Safety Effectiveness Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer</brief_title>
	<detailed_description>This open-label ( identity assign study drug know ) , observational study evaluate safety efficacy abiraterone acetate male Filipino patient advance metastatic CRPC receive prior chemotherapy contain taxane . Approximately 50 patient enrol . Abiraterone acetate administer accord approved product insert low-dose glucocorticoid ( prednisone prednisolone ) . Patient assessment base accepted clinical practice Philippines . Patients monitor 40 week .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate without neuroendocrine differentiation small cell histology Received least 1 2 cytotoxic chemotherapy regimens metastatic castration resistant prostate cancer ( CRPC ) ( least 1 regimen must contain taxane docetaxel ; chemotherapy regimen contain taxane use , consider 1 regimen ) Agrees protocoldefined use effective contraception Laboratory value within protocol define parameter Serious uncontrolled coexistent nonmalignant disease , include active uncontrolled infection Abnormal liver function Uncontrolled hypertension ( systolic blood pressure &gt; =160 mmHg diastolic blood pressure &gt; =95 mmHg ) Active symptomatic viral hepatitis chronic liver disease History pituitary adrenal dysfunction Clinically significant heart disease evidence myocardial infarction , arterial thrombotic event past 6 month , severe unstable angina , New York Heart Association ( NYHA ) Class III IV heart disease leave ventricular ejection fraction &lt; 50 % baseline Known brain metastasis History gastrointestinal disorder ( medical disorder extensive surgery ) may interfere absorption study drug Any acute toxicity due prior chemotherapy radiotherapy resolve NCICTCAE ( Version 4.0 ) Grade &lt; =1 Prior systemic treatment azole drug ( eg , fluconazole , itraconazole , ketoconazole ) within 4 week Cycle 1 , Day 1 Condition situation , investigator 's opinion , may put patient significant risk , may confound study result , may interfere significantly patient 's participation study Participation investigational drug trial within 30 day prior selection Known hypersensitivity abiraterone acetate , component formulation</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Prostate neoplasm</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Castration resistant prostate cancer</keyword>
	<keyword>Hormone refractory prostate cancer</keyword>
	<keyword>Abiraterone acetate</keyword>
	<keyword>Taxane</keyword>
</DOC>